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Contemporary Outcome Measures in Acute Stroke Research
Choice of Primary Outcome Measure and Statistical Analysis of the
Primary Outcome in Acute Stroke Trials
Barbara C. Tilley, PhD
See related articles, p 1163 and 1171.
The 2 articles in this issue1,2 are based on the recentEuropean Stroke Organization Outcomes Workshop and
provide an excellent basis for discussion of outcomes used in
stroke trials. Bath, Lees, and colleagues raise important points to
consider when choosing an outcome measure or an analysis
plan. The authors speculate that trials to identify therapeutic
benefits of effective drugs may fail to find benefits because of
problems inherent in choice of outcome measures or methods of
analysis. Early in their article, Bath and colleagues give exam-
ples of multiple ways to define an outcome and show that trial
results vary based on the definitions used. The emphasis
throughout the article is on increasing power to detect differ-
ences so effective treatments will not be missed. There are many
ways to increase power, but not all lead to the identification of
clinically meaningful differences. The authors give little mention
to the possibility of a Type 1 error, that is, declaring an
ineffective therapy effective. Type I errors can result from
searches for outcomes and analytic approaches to increase the
power to detect treatment differences after a trial is completed. It
is as important to patients that ineffective treatments are kept out
of clinical practice as it is to assure that effective treatments are
not missed.
The authors recognize that 1 outcome and 1 analytic
approach may not fit all trials. In choosing an outcome or
approach, the most important consideration is the research
question of interest. It is the trial hypothesis that should
drive the choices. As an example, at a workshop to identify
outcomes and an analytic approach for the National Insti-
tute of Neurological Disorders and Stroke Tissue Plasmin-
ogen Activator (NINDS tPA) Stroke Trial,3 Thomas Brott
stated that he would like “an outcome that tells me if my
mother is still my mother.” By implication, the question of
interest became “Does treatment with recombinant tissue-
type plasminogen activator result in recovery with minimal
or no disability?” The workshop participants determined
that the latter was an appropriate question given the risk of
cerebral hemorrhage and the expected benefit of recombi-
nant tissue-type plasminogen activator. The workshop
participants decided that success on only 1 outcome scale
provided insufficient evidence of benefit and that a 1- or
2-point mean difference on an ordinal scale would not be
convincing. The formulation of the trial question and
choice of outcomes of interest led to the decision to use a
binary global statistical test for analysis. With respect to
power, Bath and colleagues1 indicate that a dichotomous
scale may be more efficient than an ordinal scale when
treatment effects are expected to be clustered at a single
state as was expected for recombinant tissue-type plasmin-
ogen activator. Others have shown that power generally
increases when a global statistical test is used rather than
a single outcome.4 Bath and colleagues were also con-
cerned that severe adverse events could be masked by
dichotomization. However, a treatment-related imbalance
in severe adverse events would not be ignored by Data and
Safety Monitoring Boards or regulatory agencies.
When modest treatment differences are expected and/or
the risks are low, the questions of interest may be quite
different. Minimal or no disability may be too high a bar.
Thus, investigators in other trials have chosen to dichoto-
mize the modified Rankin Scale (mRS) at 0 to 2 and 2,
or 0 to 3 and 3, or 0 to 4 and 4 generally based on the
effects they expect for their therapies. These categoriza-
tions result in a lack of clarity regarding the clinical
question of interest and often little rationale is given for
the choice of cut points.5 To avoid making a choice of a cut
point, the authors recommend an ordinal scale or a sliding
scale. Bath and colleagues1 note that when studying a
therapy expected to have modest benefits and limited risk,
using the entire scale rather as a continuum rather than
dichotomizing would provide greater power to detect
differences if differences exist.
The authors make the important point that cut points for
the sliding scale must be defined before randomization.
Certainly, prespecification helps to avoid bias and Type I
errors. To design a study with a sliding scale, an investi-
gator must have extensive knowledge of the effect of
various baseline measures on subsequent outcomes using
the therapy being tested. This approach makes it difficult
to take into account the baseline covariate interactions
such as those found in at least 1 previous trial.6 A more
reasonable approach that does not lock investigators into a
set of prespecified dichotomies based on baseline covari-
ates is to use an ordinal or multiple logistic regression
analysis depending on assumptions. This approach uses the
full scale and allows for adjustment for baseline covari-
ates. It is also possible to use a global statistical test based
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on ranks7 as is currently being used in a long-term
Parkinson disease trial.8 The outcome scales can be ordi-
nal, continuous, or binary allowing use of the full spectrum
of the scales and the inclusion of multiple aspects of stroke
recovery as was done in the binary global statistical test for
the NINDS tPA Stroke Trial. The global statistical test on
ranks can be adjusted for covariates.
With respect to baseline covariates, a major omission in
the articles was consideration of time from stroke onset to
treatment. Many baseline covariates have been identified
as confounders leading to poorer outcomes across placebo
and intervention groups, but all appear to be unrelated to
treatment response. Despite multiple analyses,6 only time
from stroke onset to treatment was identified as an effect
modifier of the recombinant tissue-type plasminogen acti-
vator treatment effect9 implying that the effect of recom-
binant tissue-type plasminogen activator varies by time
from stroke onset. This interaction with time was validated
in pooled analyses that included other trials.10,11 Given the
current concept that “time is brain,” it is likely that time
from stroke outcome to treatment could be an effect
modifier for other therapies that have more modest effects
and should be considered as an important covariate in
analyses.
Last, although the authors of the 2 articles make a strong
case for the use of the mRS as the outcome scale of choice,
they acknowledge its limitations for hospitalized patients
and for short-term assessments of change. Lees and col-
leagues puzzle over why the mRS becomes less reliable
when structured interviews are used or when structured
interviews are delivered over the telephone.2 A structured
approach to using the mRS was developed to provide
better differentiation between treatment and intervention
group. The structured mRS is currently used in some of the
training programs for investigators in pharmaceutical and
National Institutes of Health trials. Unfortunately, the
structured mRS moves away from the simple construct of
a generic scale designed to measure overall disability.12
The Rankin Scale was not designed to separate other
aspects of disability from “current stroke-related” disabil-
ity. Although developed for patients with stroke, the scale
was not stroke-specific. In an early article on the Rankin
Scale discussing ways to improve agreement on the middle
categories of the mRS, van Sweiten and colleagues13
wrote: “It is important to include all causes of handicap in
patients with TIA or minor stroke because they may suffer
from other complications such as angina, myocardial
infarction, intermittent claudication, or retinal infarction.
Even nonvascular events may be side effects of the
preventive treatment that is under study and ought to be
included in the assessment.” Such a “call it as you see it”
approach was used in the NINDS Stroke Trial for the
National Institutes of Health Stroke Scale and for the mRS
as well as the other scales measuring stroke outcome. In a
small study that used an unstructured mRS, the  for
agreement was high between the mRS based on clinical
and telephone interviews but there was less agreement
between different observers.14 In addition to the Rankin
Scale, modification has been made of the National Insti-
tutes of Health Stroke Scale to measure only the results of
the current stroke. Psychometricians continually counsel
against modifying existing scales without extensive psy-
chometric testing. An example was the extensive testing of
the new Movement Disorders Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) adapted from the UPDRS by
adding a small number of questions and modifying rating
categories.15 There have been limited comparisons be-
tween the structured and unstructured approaches for
either the mRS or National Institutes of Health Stroke
Scale.
Conclusions
It is clear that the question of interest must be clearly
specified in the trial planning stage and used to choose the
measure of outcome and approach to analysis. There
should be a strong rationale for the choice of outcome
measures as reinforced by the discussion of Lees and
colleagues2 and careful consideration of the approaches to
analysis as encouraged by Bath and colleagues.1 Investi-
gators need to be concerned both about power to detect
potential beneficial effects and about the potential for Type
I errors that can be introduced if outcomes and primary
analyses are modified to increase power after a trial is
completed. There is little evidence that rigorous psycho-
metric validation has been conducted for the structured
mRS or the newer version of the National Institutes of
Health Stroke Scale. Given the continuing debates over the
choice of outcome measures, this type of validation should
be conducted before the structured mRS is considered a
recommended scale.
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